Achieve Life Sciences Inc. outlined its latest progress in the development of cytisinicline, a potential new treatment for nicotine dependence, in a recent corporate presentation. The company highlighted cytisinicline as a differentiated product with a highly selective mechanism of action, offering excellent efficacy and tolerability in both 6- and 12-week treatment durations. Achieve reported that cytisinicline is being positioned for both smoking and vaping cessation, with regulatory milestones including an expected Prescription Drug User Fee Act (PDUFA) decision by the FDA on June 20, 2026. The product is anticipated to benefit from a favorable reimbursement environment under the Affordable Care Act. The presentation also noted planned expansion opportunities for cytisinicline, including alternate administration routes and indications for relapse prevention and long-term maintenance. You can access the full presentation through the link below.